Camillia S. Azimi

Camillia S. Azimi

Auto-generated profile, based on publicly available information

Camillia S. Azimi

Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JHJoy Hsu
Joy Hsu
JHJonathan J. Hodgins
Jonathan J. Hodgins
MMMalvika Marathe
Malvika Marathe
CNChris J. Nicolai
Chris J. Nicolai
MBMarie-Claude Bourgeois-Daigneault
Marie-Claude Bourgeois-Daigneault
MAMichele Ardolino
Michele Ardolino
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.

20 October 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MAMichele Ardolino
Michele Ardolino
CACamillia S. Azimi
Camillia S. Azimi
AIAlexandre Iannello
Alexandre Iannello
TTTroy N. Trevino
Troy N. Trevino
LHLucas Horan
Lucas Horan
DRDavid H. Raulet
David H. Raulet
Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 (the “superkine” called H9) provided substantial therapeutic benefit for mice specifically bearing MHC class I–deficient tumors, but these treatments were ineffective for mice with matched MHC class I+ tumors. Cytokine efficacy was linked to the reversal of the anergic state of NK cells that specifically occurred in MHC class I–deficient tumors, but not MHC class I+ tumors. NK cell anergy was accompanied by impaired early signal transduction and was locally imparted by the presence of MHC class I–deficient tumor cells, even when such cells were a minor population in a tumor mixture. These results demonstrate that MHC class I–deficient tumor cells can escape from the immune response by functionally inactivating NK cells, and suggest cytokine-based immunotherapy as a potential strategy for MHC class I–deficient tumors. These results suggest that such cytokine therapies would be optimized by stratification of patients. Moreover, our results suggest that such treatments may be highly beneficial in the context of therapies to enhance NK cell functions in cancer patients.

9 November 2022 in Science Translational Medicine
Verified
Journal Article
Open access
DGDaniel B. Goodman
Daniel B. Goodman
CACamillia S. Azimi
Camillia S. Azimi
KKKendall Kearns
Kendall Kearns
ATAlexis Talbot
Alexis Talbot
KGKiavash Garakani
Kiavash Garakani
KRKole T. Roybal
Kole T. Roybal
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refractory cancers but have shown limited efficacy in persistent, recurrent malignancies. Here, we introduce “CAR Pooling,” a multiplexed approach to rapidly identify CAR designs with clinical potential. Forty CARs with signaling domains derived from a range of immune cell lineages were evaluated in pooled assays for their ability to stimulate critical T cell effector functions during repetitive stimulation that mimics long-term tumor antigen exposure. Several domains were identified from the tumor necrosis factor (TNF) receptor family that have been primarily associated with B cells. CD40 enhanced proliferation, whereas B cell–activating factor receptor (BAFF-R) and transmembrane activator and CAML interactor (TACI) promoted cytotoxicity. These functions were enhanced relative to clinical benchmarks after prolonged antigen stimulation, and CAR T cell signaling through these domains fell into distinct states of memory, cytotoxicity, and metabolism. BAFF-R CAR T cells were enriched for a highly cytotoxic transcriptional signature previously associated with positive clinical outcomes. We also observed that replacing the 4-1BB intracellular signaling domain with the BAFF-R signaling domain in a clinically validated B cell maturation antigen (BCMA)–specific CAR resulted in enhanced activity in a xenotransplant model of multiple myeloma. Together, these results show that CAR Pooling is a general approach for rapid exploration of CAR architecture and activity to improve the efficacy of CAR T cell therapies.

7 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JGJulie Garcia
Julie Garcia
JDJay Daniels
Jay Daniels
YLYujin Lee
Yujin Lee
IZIowis Zhu
Iowis Zhu
KCKathleen Cheng
Kathleen Cheng
JCJaehyuk Choi
Jaehyuk Choi

1 August 2019 in Current Opinion in Immunology
Verified
Journal Article
Closed access
CACamillia S. Azimi
Camillia S. Azimi
QTQizhi Tang
Qizhi Tang
KRKole T. Roybal
Kole T. Roybal
JBJeffrey A Bluestone
Jeffrey A Bluestone